Anorexia - Pipeline Insight, 2024

This “Anorexia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anorexia Understanding

Anorexia: Overview

Anorexia Nervosa is a serious eating disorder that is treatable but can be life-threatening without intervention. With over 200,000 individuals in the United States impacted per year and the highest mortality rate of any mental illness, it is important to learn the signs, symptoms, and treatment options for this disorder. Anorexia Nervosa is characterized by the National Institute of Mental Illness as individuals that have “a significant and persistent reduction in food intake leading to extremely low body weight; a relentless pursuit of thinness; a distortion of body image and intense fear of gaining weight; and extremely disturbed eating behavior. Anorexia has no single cause. it seems that a genetic predisposition is necessary but not sufficient for development of the disorder. A positive diagnosis of psychologically driven weight loss can be made in most patients, without the need for a battery of complex investigations to reach a diagnosis of exclusion. Basic medical investigations, blood tests, electrocardiography, weighing, and measuring the patient provide an opportunity for the patient to return (to discuss the results) and can uncover psychological problems.

Strategies include:

• cognitive-behavioral therapy (CBT), which can help the person find new ways of thinking, behaving, and managing stress
• family and individual counseling, as appropriate
• nutritional therapy, which provides information on how to use food to build and maintain health
• medication to treat depression and anxiety
• supplements to resolve nutritional deficiencies
• hospital treatment, in some cases

Anorexia Emerging Drugs Chapters

This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anorexia Emerging Drugs

ART2713: Artelo BiosciencesART27.13 is a dual agonist program targeting cancer, cancer-related anorexia and weight loss. It is a clinic-ready, potent, peripherally restricted CB1/CB2 synthetic agonist. Existing clinical data with ART27.13 suggests meaningful potential for the treatment of cancer-related anorexia and weight loss (cachexia). In five Phases I clinical studies including over 200 subjects, ART27.13 demonstrated a statistically significant and dose-proportional increase in body weight. In ongoing consultation with regulatory authorities, we plan to advance ART27.13 as a multi-modal supportive care therapy for cancer patients suffering from anorexia or weight loss. Numerous non-peripherally restricted CB1 and CB2 agonists have shown promising results as anti-tumor drugs, yet their profile made them unsuitable for further development. It is currently in Phase I/II stage of development for Anorexia and is being developed by Artelo Biosciences in collaboration with AstraZeneca.

Anorexia: Therapeutic Assessment

This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anorexia

There are approx. 5+ key companies which are developing the therapies for Anorexia. The companies which have their Anorexia drug candidates in the mid to advanced stage, i.e. Phase I/II include, Artelo Biosciences.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-Stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anorexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptide
• Antibiotics
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anorexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia R&D. The therapies under development are focused on novel approaches to treat/improve Anorexia.

Anorexia Report Insights

• Anorexia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anorexia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anorexia drugs?
• How many Anorexia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anorexia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anorexia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anorexia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amgen
• COMPASS Pathways
• Benuvia Therapeutics
• Artelo Biosciences
• RaQualia Pharma
• Receptor Life Sciences
• Pfizer

Key Products

• Romosozumab
• Psilocybin
• RQ 00433412
• ART 2713
• PF-07258669